Skip to content

Transcutaneous acupoint electrical stimulation combined bilateral transverse abdominal muscle block and ondansetron for prevention of gynecological laparoscopic surgery in patients with postoperative nausea and vomiting

A single-center, randomized, double-blind, controlled study of transcutaneous acupoint electrical stimulation combined with bilateral transverse abdominal muscle block and ondansetron in the prevention and treatment of postoperative nausea and vomiting in patients undergoing gynecological laparoscopic surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058283
Enrollment
Unknown
Registered
2022-04-04
Start date
2022-04-20
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting (PONV)

Interventions

Experimental group:Induction of anesthesia begins 30 minutes before injection of percutaneous electrical stimulation (TEAS) at Neiguan, Zusanli and Hegu points. Use density wave, patient can tolerate
Control group:The electrodes were placed at Neiguan, Zusanli and Hegu points 30 minutes before anesthesia induction without electrical stimulation

Sponsors

General Hospital of Northern Theater Command
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Gynecological laparoscopic surgery under elective general anesthesia; 2. Aged 18-50 years; 3. Body Mass index (BMI) : 18-30kg/m^2; 4. American Society of Anesthesiologists (ASA) Grade I to II; 5. Fully understand the test plan and purpose and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Vomiting or retching occurred 24 hours before surgery, and antiemetics were accepted; 2. Treatment with steroids or psychoactive drugs or a history of other substance abuse; 3. Patients with persistent vomiting due to other diseases (such as acute gastritis, gastric mucosal prolapse, pyloric spasm or obstruction and other gastrointestinal diseases, acute pancreatitis, uremia and neuropathic vomiting); 4. Diabetes mellitus, liver and kidney dysfunction, cognitive dysfunction, and history of severe cardiovascular diseases (such as myocardial infarction, unstable angina, etc.); 5. Pacemaker implantation; 6. Those who refuse to accept TAP block or are allergic to local anesthetics; 7. Skin rash or infection occurs when the acupoint irritates the skin area; 8. Patients who switched to open surgery during laparoscopic surgery; 9. Participants who have participated in other clinical trials within 3 months.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative nausea and vomiting (POVN);

Secondary

MeasureTime frame
Simplified PONV impact scale scores;Pain visual analog scale score;40 items recovery quality quantification table;Number of early pressurized dosing or discontinuation of intravenous self-administered analgesic pumps;Number of rescue antiemetics used;Number of rescue antiemetics used;Occurrence of other complications such as itchy skin, dizziness, headache, etc.;

Countries

China

Contacts

Public ContactLi Lin
lilinslashofmine@qq.com+86 13304042711

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026